All In Biotech

Drug Trial Radar · NCT06253715

Shortened Regimen for Drug-susceptible TB in Children

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

860

Planned (sponsor's estimate)

Start

Jan 15, 2025

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Agency for International Development (USAID); Medical Research Council, South Africa; The ELMA Foundation
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 days, up to 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.

Conditions

  • Tuberculosis
  • Tuberculosis, Pulmonary
  • Tuberculosis, Lymph Node
  • Mycobacterium Tuberculosis

Interventions

  • IsoniazidDrug

    Once daily weight-based dose

  • RifampinDrug

    Once daily weight-based dose

  • PyrazinamideDrug

    Once daily weight-based dose

  • EthambutolDrug

    Once daily weight-based dose

  • RifapentineDrug

    Once daily weight-based dose

  • MoxifloxacinDrug

    Once daily weight-based dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TB disease-free survival at 48-weeksTime frame: Measured from study entry through week 48
  2. Proportion of participants with grade 3 or higher adverse events over 28 weeksTime frame: Measured from study entry through Week 28

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Indian Council of Medical Research - National Institute for Research in Tuberculosis

    Chennai, India · Recruiting

  • Dr. D.Y. Patil Medical College, Hospital and Research Center

    Pune, India · Recruiting

  • Faculty of Medicine, Universitas Padjadjaran

    Bandung, Indonesia · Recruiting

  • Instituto Nacional de Saúde (INS)

    Maputo, Mozambique · Recruiting

  • Africa Health Research Institute (AHRI)

    Durban, South Africa · Recruiting

  • MU-JHU Care Ltd

    Kampala, Uganda · Recruiting

  • University of Zambia, School of Medicine

    Lusaka, Zambia · Recruiting

  • Arthur Davison Children's Hospital

    Ndola, Zambia · Recruiting

  • Harare Health and Research Consortium (HHRC)

    Harare, Zimbabwe · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.